| scholarly article | Q13442814 |
| P50 | author | Gary K Yang | Q59679649 |
| Timothy J Kieffer | Q84264530 | ||
| P2093 | author name string | Robert Baker | |
| Tianjiao Zhang | |||
| Garth L Warnock | |||
| Ali Asadi | |||
| Yukihiro Fujita | |||
| Rennian Wang | |||
| Rhonda D Wideman | |||
| Ziliang Ao | |||
| Yin Nam Kwok | |||
| Travis Webber | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glucose | Q37525 |
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 1966-1975 | |
| P577 | publication date | 2010-02-04 | |
| P1433 | published in | Gastroenterology | Q4039279 |
| P1476 | title | Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion | |
| P478 | volume | 138 |
| Q33541007 | A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control |
| Q38564721 | A Review of Diabetes Mellitus and Exposure to the Environmental Toxicant Cadmium with an Emphasis on Likely Mechanisms of Action |
| Q34410733 | A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. |
| Q38815060 | A synopsis of factors regulating beta cell development and beta cell mass |
| Q35043520 | Alterations of glucose-dependent insulinotropic polypeptide and expression of genes involved in mammary gland and adipose tissue lipid metabolism during pregnancy and lactation |
| Q26749205 | Alternative form of glucose-dependent insulinotropic polypepide and its physiology |
| Q58577638 | Antagonistic interaction between Nodal and insulin modulates pancreatic β-cell proliferation and survival |
| Q26749211 | Carbohydrate-induced secretion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 |
| Q90244034 | Characterisation of Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonists in Rodent Pancreatic Beta Cells and Mice |
| Q46878138 | Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes |
| Q37613876 | Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects |
| Q58572799 | Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1 |
| Q39329866 | Do we know the true mechanism of action of the DPP-4 inhibitors? |
| Q36560559 | Ectopic expression of GIP in pancreatic β-cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides. |
| Q36990110 | Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin |
| Q96024995 | Establishment of novel specific assay for short-form glucose-dependent insulinotropic polypeptide and evaluation of its secretion in nondiabetic subjects |
| Q36402230 | Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: how markers of β-cell loss may assist. |
| Q26997149 | GLP-1-based strategies: a physiological analysis of differential mode of action |
| Q26751480 | GLP2: an underestimated signal for improving glycaemic control and insulin sensitivity |
| Q35743737 | Gastric inhibitory polypeptide (GIP) is selectively decreased in the roux-limb of dietary obese mice after RYGB surgery |
| Q42562477 | Generation of functional insulin-producing cells in the gut by Foxo1 ablation |
| Q48586968 | Glucose metabolism is altered after loss of L cells and α-cells but not influenced by loss of K cells |
| Q49218095 | Gut hormone polyagonists for the treatment of type 2 diabetes |
| Q37193295 | Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls |
| Q33753169 | Incretin receptor null mice reveal key role of GLP-1 but not GIP in pancreatic beta cell adaptation to pregnancy |
| Q89767551 | Intra-islet GLP-1, but not CCK, is necessary for β-cell function in mouse and human islets |
| Q37236496 | Intraislet SLIT-ROBO signaling is required for beta-cell survival and potentiates insulin secretion |
| Q38409880 | Islet α cells and glucagon--critical regulators of energy homeostasis |
| Q37811410 | K-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease |
| Q36720548 | Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor. |
| Q42117088 | Menin and GIP are inversely regulated by food intake and diet via PI3/AKT signaling in the proximal duodenum |
| Q36599662 | N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor |
| Q26777654 | New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders |
| Q37814881 | Nutrition and L and K-enteroendocrine cells |
| Q43085677 | Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. |
| Q40181768 | Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1-30) expression is upregulated in diabetes and PEGylated GIP(1-30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice |
| Q33787970 | Paracrine signalling loops in adult human and mouse pancreatic islets: netrins modulate beta cell apoptosis signalling via dependence receptors |
| Q38248682 | Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors |
| Q38122004 | Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity. |
| Q35760279 | Physiology of incretins in health and disease |
| Q27027920 | Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease |
| Q91121478 | Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications |
| Q51315256 | Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes. |
| Q92099033 | Premises for Cholecystokinin and Gastrin Peptides in Diabetes Therapy |
| Q50231932 | Protective effects of glycyrrhizic acid from edible botanical glycyrrhiza glabra against non-alcoholic steatohepatitis in mice |
| Q42289792 | RNA-Seq analysis of enteroendocrine cells reveals a role for FABP5 in the control of GIP secretion |
| Q94545098 | Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes |
| Q53207032 | Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. |
| Q33812543 | Role of endogenous GLP-1 and GIP in beta cell compensatory responses to insulin resistance and cellular stress |
| Q89850039 | Serum Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) in association with the Risk of Gestational Diabetes: A Prospective Case-Control Study |
| Q92924483 | Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors |
| Q38372992 | The equine glucose-dependent insulinotropic polypeptide receptor: A potential therapeutic target for insulin dysregulation |
| Q28590140 | The expression and function of glucose-dependent insulinotropic polypeptide in the embryonic mouse pancreas |
| Q36193707 | The role of the Wnt signaling pathway in incretin hormone production and function |
| Q33604681 | Type 2 diabetes susceptibility gene expression in normal or diabetic sorted human alpha and beta cells: correlations with age or BMI of islet donors |
Search more.